Everything is the same. And, it could go either way. Pros: Top experts in field are involved with INO, very good institutional investors emerged with last round of equity, they have the cash now and the technology area INO is focused on it awfully hot. If they have positive results, the stock goes to $20, easily. Cons: This amount of attention (lots of PR) could backfire if they miss. They have plenty of ammo left, but stock could drop 50% or more with all this focus on this one trial. I always liked the risk/reward on INO, but now its all been amplified and its getting me less comfortable, because pendulum swings of reactive investors. Oh, AF is an idiot btw. He's cost me hundreds of thousands of $$. He should not have a job at TSC.